# Abivax Shares Fall About 9% After Scorpion Research Short Report

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/62362
Published: 2026-11-20T22:40:23.000Z
Updated: 2026-11-20T22:40:23.000Z
Section: Business

> The report criticized the clinical development of obefazimod, Abivax’s ulcerative colitis candidate. Scorpion Research disclosed a short position in the company.

Abivax shares closed down about 9% Friday, Nov. 20, 2026, after Scorpion Research issued a short report criticizing the clinical development of the company’s ulcerative colitis candidate, obefazimod.

Scorpion Research disclosed that it holds a short position in Abivax. The report’s criticism was directed at obefazimod’s clinical development.


